Juluca combines GSK’s already approved integrase inhibitor Tivicay (dolutegravir) with Janssen’s non-nucleoside reverse transcriptase inhibitor Edurant (rilpivirine), to produce a regimen that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback